Just Healthcare

Just Healthcare

Share this post

Just Healthcare
Just Healthcare
Discontinuing JAK Inhibitors and Hair Loss in Severe Alopecia Areata Patients
Copy link
Facebook
Email
Notes
More

Discontinuing JAK Inhibitors and Hair Loss in Severe Alopecia Areata Patients

Exploring the necessity of long-term baricitinib therapy for sustained hair regrowth in alopecia areata patients.

Naveen Sankar S's avatar
Naveen Sankar S
Aug 19, 2024
∙ Paid
3

Share this post

Just Healthcare
Just Healthcare
Discontinuing JAK Inhibitors and Hair Loss in Severe Alopecia Areata Patients
Copy link
Facebook
Email
Notes
More
Share
A detailed image illustrating a person with severe alopecia areata experiencing hair regrowth due to JAK inhibitor therapy. The scene is split into two halves: the left side shows the person with noticeable hair regrowth, while the right side depicts the same person after discontinuing the therapy, showing significant hair loss. The background is minimalistic, focusing on the contrast between the two states. The person appears hopeful on the left and concerned on the right, capturing the emotional impact of the treatment's success and the relapse.

Topline:

Discontinuing baricitinib therapy after successful hair regrowth in severe alopecia areata patients led to significant hair loss, highlighting the need for ongoing treatment to maintain benefits.

Study Details:

Severe alopecia areata, an autoimmune condition resulting in hair loss, has seen advancements in treatment with the introduction of Janus …

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Just Healthcare
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More